Browse
Submit Data
Databases
API
Help

Dataset Information

8 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A phase II study of alternate-day administration of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination as first-line treatment in patients with metastatic colorectal cancer.

ABSTRACT: Interventions: S-1 80-120 (mg/day) Monday, Wednesday, Friday, Sunday Leucovorin 50 (mg/day) Monday, Wednesday, Friday, Sunday Oxaliplatin 85 (mg/m2) day1 Bevacizumab 5 (mg/kg) day 1 every 2 weeks Primary outcome(s): Objective response rate as assessed by independent ragiologic review Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2635716 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase II study of oxaliplatin reintroduction treated with biweekly S-1 plus oxaliplatin (SOX) in patients with metastatic colorectal cancer.(ORION2)

Project description:Interventions: Oxaliplatin 85 mg/m2, day1 S-1 80-120 mg/day, day 1-7 or alternate-day every 2 weeks Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

| 2628628 | ecrin-mdr-crc

Multicenter Phese II Study of SOX plus Bevacizumab Therapy with Oxaliplatin Stop-and-Go Strategy and Oral S-1 plus Bevacizumab Maintenance Therapy in Advanced Colorectal CancerC

Project description:Interventions: (1)Initial therapy : SOX+bevacizumab therapy Bev : 7.5 mg/kg (90 min) L-OHP : 130 mg/m2 (120 min) S-1 : 80 - 120 mg/day (Day1-15) (2)Maintenance therapy : S-1+bevacizumab therapy Bev : 7.5 mg/kg (90 min) S-1 : 80 - 120 mg/day (Day1-15) (3)Reintroduced therapy : SOX+bevacizumab therapy Primary outcome(s): DDC ; Duration of disease control) Study Design: Single arm Non-randomized

| 2627046 | ecrin-mdr-crc

A Phase II Study of Bi-weekly XELOX with Bevacizumab for patient with Metastatic Colorectal Cancer as first-line chemotherapy

Project description:Interventions: XELIRI plus bevacizumab therapy /Capecitabine;2,000 mg/m2 day1-8(orally, day1 after dinner; day8 after breakfast) /Oxaliplatin 85 mg/m2 day1 /Bevacizumab: 5mg/kg day 1 The treatment is repeated every two weeks until disease progression or severe toxicity Primary outcome(s): progression free survival Study Design: Single arm Non-randomized

| 2625648 | ecrin-mdr-crc

Chacterization of Day 1 and Day 5 Atlantic salmon adherent head kidney leukocytes (HKLs)

Project description:Transcriptional profiling of Atlantic salmon adherent HKLs that were cultured for 1 day (24 h) and cultured for 5 days (120 h). Our previous data (RNA-seq, morphology and phagocytosis) indicate that Day 1 cells are predominatly monocytes while Day 5 cells are predominatly macrophages.

2021-04-29 | GSE173493 | GEO

Helianthus annuus strain:85 day | cultivar:commercial

Project description:Helianthus annuus strain:85 day | cultivar:commercial Transcriptome or Gene expression

| PRJNA771647 | ENA

Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer(WJOG9216G)

Project description:Interventions: Arm A: FOLFIRI+Rmab treatment Rmab:8 mg/kg/day1 l-leucovorin (l-LV):200 mg/m2/day1 irinotecan (IRI): 180 mg/m2/day1 bolus 5-FU:400 mg/m2/day1 infusional 5-FU:2400 mg/m2/day1-3 Every 2 eeks Arm B: FOLFOXIRI+Rmab treatment Induction therapy: 8 courses (maximum of 12 courses) Rmab:8 mg/kg/day1 IRI:165 mg/m2/day1 l-LV:200 mg/m2/day1 oxaaliplatin (OX):85 mg/m2/day1 infusional 5-FU: 3200 mg/m2/day1-3 Every 2 weeks Maintenance therapy 5-FU/l-LV+Rmab, every 2 week Primary outcome(s): Objective response rate Study Design: Parallel Randomized

| 2641746 | ecrin-mdr-crc

Nicotinamide Mononucleotide administration prevents doxorubicin-induced cardiotoxicity and loss in physical activity in mice.

Project description:In this study we investigated whether nicotinamide mononucleotide (NMN) could protect against Doxorubicin-induced cardiotoxicity and physical dysfunction in vivo. To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic. In the acute study, C57BL6/J (B6) mice were injected intraperitoneally (i.p.) once with Doxo (20 mg/kg) and NMN (180 mg/kg/day, i.p.) was administered daily for five days before and after the Doxo injection. In the chronic study, B6 mice received a cumulative dose of 20 mg/kg Doxo administered in fractionated doses for five days. NMN (500 mg/kg/day) was supplied in the mice’s drinking water beginning five days before the first injection of Doxo and continuing for 60 days after.

2023-01-11 | GSE221003 | GEO

Transcription profiling of rat AFTER IN vivo administration OF Gamendazole AND Lonidamine

Project description:rat testis time changes; Experimental details are found at Tash et al, Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets HSP-90, eEF1A, and stimulates IL-1 transcription in Sertoli cells, Biol. Reprod. (2007) under review Experiment Overall Design: Adult male rats administered single ip dose of 6mg/kg Gamendazole or 25 mg/kg lonidamine or vehicle control (buffered DMSO) - testes harvested at 0 4 12 and 24 hr - 3 chips used for each time point

2008-04-10 | E-GEOD-8485 | biostudies-arrayexpress

Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer (WJOG9216G)

Project description:Interventions: Arm A: FOLFIRI plus ramucirumab (Rmab) treatment - Rmab: 8 mg/kg/day1 - l-leucovorin (l-LV): 200 mg/m2/day1 - irinotecan (IRI): 180 mg/m2/day1 - bolus 5-FU: 400 mg/m2/day1 - infusional 5-FU: 2400 mg/m2/day1-3 Every 2 weeks Arm B: FOLFOXIRI plus Rmab treatment Induction therapy: 8 courses (maximum of 12 courses) - Rmab: 8 mg/kg/day1 - IRI: 165 mg/m2/day1 - l-LV: 200 mg/m2/day1 - oxaliplatin (OX): 85 mg/m2/day1 - infusional 5-FU: 3200 mg/m2/day1-3 Every 2 weeks Maintenance therapy: 5-FU/l-LV+Rmab, every 2 weeks Primary outcome(s): Objective response rate Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose

| 2614896 | ecrin-mdr-crc

Single-cell profiling of cell cultures during endoMT induction.

Project description:Single-cell RNA sequencing (scRNAseq) data from EndoMT Day 1 dcas9-KRAB-MeCP2 (KRAB Control Day1), EndoMT Day 3 dcas9-KRAB-MeCP2 (KRAB Control Day3), and EndoMT Day 3 dcas9-KRAB-MeCP2 + rs117430032 gRNA (rs117430032i) cells.

2022-12-16 | GSE193206 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data